Received Mar 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 3RT93 | — |
they administered a dose of Kinrix to a 3 years 7 months old patient; Different products for primary series; This non-serious case was reported by a nurse via call center representative and described the occurrence of inappropriate age at vaccine administration in a 3-year-old female patient who received DTPa-IPV (Kinrix) (batch number 3RT93) for prophylaxis. Previously administered products included Vaxelis (received 1st dose on 20th April 2023) and Pediarix (received 2nd dose on 11th November 2024). On 25-FEB-2025, the patient received the 3rd dose of Kinrix. On 25-FEB-2025, an unknown time after receiving Kinrix, the patient experienced inappropriate age at vaccine administration (Verbatim: they administered a dose of Kinrix to a 3 years 7 months old patient) and inappropriate schedule of vaccine administered (Verbatim: Different products for primary series). The outcome of the inappropriate age at vaccine administration and inappropriate schedule of vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date:28-FEB-2025 The reporter contacted to request information about how to proceed after a three-year 7 month old patient accidentally received a dose of Kinrix, which led to inappropriate age at vaccine administration. They mentioned that the patient received doses of DtAP and Polio previously, with the first dose being on 20th April 2023, the second dose being on 7th November 2024 and the third dose being the one administered on 25th February 2025, which led to inappropriate schedule of vaccine administered. During the phone call they also requested information about how to space out the different components of Kinrix, and the information was read after letting the health care professional know that this information was in a standard response letter for Pediarix. The reporter asked if there were any grace period or the dose was count as valid. The Vaccine Administration Facility was the same as Primary Reporter. They mentioned that they consented to receive follow up.